Original Article July 15, 2026 July 15, 2026

Topical losartan as a novel therapeutic approach for corneal scars: clinical outcomes from a case series

DOI: 10.37039/1982.8551.20260064

ABSTRACT

The objective was to investigate the efficacy of topical losartan in treating corneal scars in patients with varying clinical backgrounds. A case series with six patients diagnosed with corneal scars resulting from herpetic keratitis or complicated photorefractive keratectomy were treated with topical losartan at a concentration of 0.8 mg/mL. Each patient underwent comprehensive ophthalmologic evaluations, including anterior segment optical coherence tomography and corneal tomography, to assess clinical outcomes after treatment. Improvement in visual acuity was noted in five out of six patients. Patient-reported outcomes and imaging demonstrated significant reductions in corneal scars and enhanced transparency following treatment. However, one patient continued to have stable visual acuity despite a decrease in opacity after 7 months of therapy. This series highlights the potential of topical losartan as a novel approach for managing corneal scars by targeting the TGF-β signalling pathway. With corroborating imaging assessments showing measurable improvements, losartan is a promising adjunctive therapy for corneal scarring. Vehicle-controlled clinical trials are warranted to establish its long-term efficacy and safety across diverse populations and clinical settings.